These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 10796054)

  • 1. Inverse agonism at heptahelical receptors: concept, experimental approach and therapeutic potential.
    Daeffler L; Landry Y
    Fundam Clin Pharmacol; 2000; 14(2):73-87. PubMed ID: 10796054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inverse agonism and the regulation of receptor number.
    Milligan G; Bond RA
    Trends Pharmacol Sci; 1997 Dec; 18(12):468-74. PubMed ID: 9458695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of inverse agonism at G-protein-coupled receptors.
    Strange PG
    Trends Pharmacol Sci; 2002 Feb; 23(2):89-95. PubMed ID: 11830266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional differences between full and partial agonists: evidence for ligand-specific receptor conformations.
    Seifert R; Wenzel-Seifert K; Gether U; Kobilka BK
    J Pharmacol Exp Ther; 2001 Jun; 297(3):1218-26. PubMed ID: 11356949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. G-protein coupled receptors: conformations and states.
    Strange PG
    Biochem Pharmacol; 1999 Oct; 58(7):1081-8. PubMed ID: 10484065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors.
    Seifert R; Wenzel-Seifert K
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Nov; 366(5):381-416. PubMed ID: 12382069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The human formyl peptide receptor as model system for constitutively active G-protein-coupled receptors.
    Seifert R; Wenzel-Seifert K
    Life Sci; 2003 Sep; 73(18):2263-80. PubMed ID: 12941430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural requirements for inverse agonism and neutral antagonism of indole-, benzimidazole-, and thienopyrrole-derived histamine H4 receptor ligands.
    Schneider EH; Strasser A; Thurmond RL; Seifert R
    J Pharmacol Exp Ther; 2010 Aug; 334(2):513-21. PubMed ID: 20484153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physiological effects of inverse agonists in transgenic mice with myocardial overexpression of the beta 2-adrenoceptor.
    Bond RA; Leff P; Johnson TD; Milano CA; Rockman HA; McMinn TR; Apparsundaram S; Hyek MF; Kenakin TP; Allen LF
    Nature; 1995 Mar; 374(6519):272-6. PubMed ID: 7885448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inverse agonism and constitutive activity as functional correlates of serotonin h5-HT(1B) receptor/G-protein stoichiometry.
    Newman-Tancredi A; Audinot V; Moreira C; Verrièle L; Millan MJ
    Mol Pharmacol; 2000 Nov; 58(5):1042-9. PubMed ID: 11040052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Agonist and inverse agonist activity at the dopamine D3 receptor measured by guanosine 5'--gamma-thio-triphosphate--35S- binding.
    Malmberg ; Mikaels ; Mohell N
    J Pharmacol Exp Ther; 1998 Apr; 285(1):119-26. PubMed ID: 9536001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inverse agonists: tools to reveal ligand-specific conformations of G protein-coupled receptors.
    Prather PL
    Sci STKE; 2004 Jan; 2004(215):pe1. PubMed ID: 14722344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do recent operational studies indicate that a single state model is no longer applicable to G protein-coupled receptors?
    Bond RA
    Ann N Y Acad Sci; 1997 May; 812():92-7. PubMed ID: 9186724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy as a vector: the relative prevalence and paucity of inverse agonism.
    Kenakin T
    Mol Pharmacol; 2004 Jan; 65(1):2-11. PubMed ID: 14722230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of active and inactive states of CB1 receptor and the differential binding state modulation by cannabinoid agonists, antagonists and inverse agonists.
    Gullapalli S; Amrutkar D; Gupta S; Kandadi MR; Kumar H; Gandhi M; Karande V; Narayanan S
    Neuropharmacology; 2010 Jun; 58(8):1215-9. PubMed ID: 20214912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Agonism and inverse agonism at dopamine D2-like receptors.
    Strange PG
    Clin Exp Pharmacol Physiol Suppl; 1999 Apr; 26():S3-9. PubMed ID: 10386247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug efficacy at guanine nucleotide-binding regulatory protein-linked receptors: thermodynamic interpretation of negative antagonism and of receptor activity in the absence of ligand.
    Costa T; Ogino Y; Munson PJ; Onaran HO; Rodbard D
    Mol Pharmacol; 1992 Mar; 41(3):549-60. PubMed ID: 1312216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Control of bronchial contractility, regulation of receptor activity and expression].
    Landry Y; Daeffler L
    Rev Mal Respir; 2000 Jun; 17(2 Pt 2):539-43. PubMed ID: 10939111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of inverse agonism of antipsychotic drugs at the D(2) dopamine receptor: use of a mutant D(2) dopamine receptor that adopts the activated conformation.
    Wilson J; Lin H; Fu D; Javitch JA; Strange PG
    J Neurochem; 2001 Apr; 77(2):493-504. PubMed ID: 11299312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inverse agonists and serotonergic transmission: from recombinant, human serotonin (5-HT)1B receptors to G-protein coupling and function in corticolimbic structures in vivo.
    Millan MJ; Gobert A; Audinot V; Dekeyne A; Newman-Tancredi A
    Neuropsychopharmacology; 1999 Aug; 21(2 Suppl):61S-67S. PubMed ID: 10432490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.